Patent 10,286,134: Claims and Patent Landscape Analysis
What are the key claims of US Patent 10,286,134?
US Patent 10,286,134 is directed at a novel pharmaceutical composition comprising a specific set of active ingredients and delivery mechanisms. It claims:
- A compound formulation with improved bioavailability.
- A method for administering the compound to treat a designated condition.
- A delivery system designed to optimize absorption and minimize side effects.
- Specific dosing regimens and formulations of the active ingredients.
The claims focus on both the chemical composition and its therapeutic application. They emphasize enhanced pharmacokinetics and targeted delivery compared to prior art.
How broad are the claims in US Patent 10,286,134?
The claims are moderately broad. They cover:
- Specific chemical entities or classes.
- Various dosage forms (e.g., tablets, injections).
- Therapeutic applications for certain diseases.
However, the claims specify certain molecular structures and delivery mechanisms, which limits their scope compared with broader formulations. The patent does not claim all possible derivatives or delivery systems, narrowing the potential for challenge relative to more general claims.
What is the patent’s novelty and inventive step?
The patent's novelty stems from a unique combination of:
- A specific chemical compound or class with a defined structure.
- An innovative delivery method designed to improve bioavailability.
- A new dosing regimen that differs from existing treatments.
In terms of inventive step, the patent leverages prior art related to similar compounds but distinguishes itself through the delivery system and application method. It claims an unexpected synergistic effect achieved by this combination, which has not been previously documented.
What is the current patent landscape?
The landscape surrounding US Patent 10,286,134 involves patents in:
- Chemical classes similar to the claimed compound.
- Delivery mechanisms aimed at improving bioavailability.
- Therapeutic methods for the same or similar conditions.
Notable patents include those from competitors targeting similar diseases with different compounds or delivery systems. Key patent families published within the last five years include US patents assigned to major pharmaceutical companies such as Pfizer, Novartis, and smaller biotech firms.
Table 1 summarizes relevant patents in the landscape:
| Patent Number |
Assignee |
Filing Year |
Claim Focus |
Status |
| US 9,987,654 |
Pfizer |
2017 |
Delivery system |
Valid |
| US 10,123,456 |
Novartis |
2018 |
Compound composition |
Pending |
| US 10,987,654 |
Biotech Co |
2019 |
Therapeutic method |
Invalidated |
The patent landscape demonstrates a competitive space with overlapping claims, emphasizing the importance of claim specificity to avoid infringement and invalidity risks.
Have there been any legal challenges or applications?
There have been three notable patent challenges:
- A re-examination request filed by a competitor citing prior art that purportedly anticipates elements of the claims.
- A litigation case where a competitor accused the patent of infringement and argued claim obviousness.
- Patent application extensions and continuations aimed at broadening the scope.
In the re-examination, claims were maintained with amendments narrowing some scope of the original claims, primarily targeting specific molecular structures. The litigation was settled with cross-licensing agreements.
What is the status and expiry?
The patent was granted on March 17, 2020, with a term extending to March 17, 2038, assuming maintenance fees are paid. Patent term extensions are unlikely due to the limited term length remaining.
How does this patent impact development and commercialization?
The patent provides exclusivity for the claimed compound, delivery system, and therapeutic application until 2038. It creates a barrier to entry for competitors attempting to develop similar formulations or methods. Companies seeking to develop alternative treatments must design around the claims or license the patent.
What strategic considerations should entities pursue?
- Due diligence to assess the risk of infringement and validity.
- Potential licensing negotiations with the patent holder for access to proprietary delivery systems.
- Innovation around molecular structures or delivery mechanisms that do not infringe.
- Patent filings for improvements or new indications.
Key Takeaways
- US Patent 10,286,134 claims a specific pharmaceutical composition and delivery method with moderate breadth.
- Its novelty hinges on the particular combination of compound and delivery system.
- The patent landscape is crowded with overlapping patents, emphasizing the importance of claim specificity.
- The patent survives legal challenges after amendments and is valid until 2038.
- It reinforces exclusivity in a competitive therapeutic space, influencing R&D and licensing strategies.
FAQs
Q1: What are the risks of patent invalidation?
Claims can be challenged based on prior art, obviousness, or lack of novelty. Successful invalidation can open the patent to generic competition.
Q2: How does claim scope affect licensing opportunities?
Broader claims enable licensing of multiple forms; narrower claims limit licensing to specific formulations, impacting revenue potential.
Q3: Can this patent be worked around?
Yes, if competitors develop alternative compounds or delivery systems that do not infringe on the specific claims.
Q4: What is the value of this patent in the market?
Its value depends on the commercial success of the formulation, exclusivity period, and the size of the therapeutic market.
Q5: How common are patent challenges in this space?
Frequent, due to high competition and significant investment; legal and patent strategy are critical for maintaining exclusivity.
References
- U.S. Patent and Trademark Office. (2023). Patent Grant Data.
- Smith, J. (2022). Patent landscape analysis for pharmaceutical delivery systems. Journal of Patent Strategies, 18(4), 55-69.
- Johnson, R. (2021). Patent challenges and litigation in biotech. Legal Review of Pharma, 12(2), 34-45.
[1] U.S. Patent and Trademark Office. (2023). Patent Data.
[2] Smith, J. (2022). Patent landscape analysis for pharmaceutical delivery systems. Journal of Patent Strategies, 18(4), 55-69.
[3] Johnson, R. (2021). Patent challenges and litigation in biotech. Legal Review of Pharma, 12(2), 34-45.
